



Heather Morehouse Ettinger, Ph.D.

Partner

875 Third Avenue
New York, NY 10022
212.704.6136 telephone
212.704.6288 facsimile
heather.ettinger@troutman.com

Heather Morehouse Ettinger, Ph.D., is a partner in the law firm of Troutman Sanders LLP and is based in the firm's New York office.

Heather focuses her practice on intellectual property due diligence and transaction drafting, intellectual property litigation, and patent counseling and procurement in the biotechnical and pharmaceutical fields. She regularly handles domestic and international patent portfolios, and due diligence studies for clients, including major corporations and research institutes. She also regularly counsels in Hatch-Waxman issues and has significant Hatch-Waxman litigation experience. She has extensive experience performing due diligence, agreement drafting, counseling, and litigating on patent matters in areas such as recombinant molecular biology, pharmaceutical formulations, genetically modified plants, enzyme and other large molecule technology and small molecule chemistry. She has procured patents covering inventions in a wide range of fields in the life sciences. She has counseled clients in multi-billion dollar intellectual property transactions.

Heather earned her J.D., cum laude, from Fordham University School of Law and her Ph.D. in biological and biomedical sciences from Harvard University. She received her B.S., summa cum laude, in biology from Tufts University.

While at Tufts University, Heather was elected to Phi Beta Kappa.

Heather is admitted to practice in New York and New Jersey, and before the U.S. District Court for the Southern District of New York. She is a registered patent attorney with the U.S. Patent and Trademark Office.

Representative Matters

- Served as lead IP counsel for Bain Capital Life Sciences in its \$70M purchase of Dicerna Pharmaceuticals preferred stock.
- Served as lead IP counsel for a major pharmaceutical company in its \$32 billion acquisition of another pharmaceutical company. Handled review of freedom-to-operate and patent exclusivity for more than 20 commercial and pipeline products that focus on rare disease treatments.
- Due diligence and transaction drafting for major pharmaceutical company in

Practice

- Academic and Research Institutions
- Healthcare
- Intellectual Property
- Life Sciences
- Life Sciences – Intellectual Property
- Litigation
- Patent Litigation
- Patent Prosecution, Counseling and Portfolio Management

Education

- Fordham University (J.D., cum laude, 2006)
- Harvard University (Ph.D., 2001)
- Tufts University (B.S., summa cum laude, 1995)

Work Experience

- Partner, Troutman Sanders LLP, 2013-present
- Counsel, Troutman Sanders LLP, 2012

Bar and Court Admissions

- New York
- New Jersey
- U.S. Patent and Trademark Office
- U.S. District Court for the Southern District of New York
- U.S. District Court for the Southern District of New York

Distinctions

- Selected as a "Rising Star" by *New York Metro Super Lawyers* (2013-2014).

Languages

- Italian

its \$6.5 billion acquisition of a biotechnology company focused on the treatment for hereditary angioedema, or HAE. Also counseled on royalty provisions, trademark coverage, ownership issues and patent exclusivity.

- Due diligence and transaction drafting for major pharmaceutical company in its \$5.2 billion acquisition of a pharmaceutical company that specializes in treatments for rare diseases.
- Due diligence and transaction drafting for major pharmaceutical company in its acquisition of an ophthalmology company.
- Successfully defended major pharmaceutical company in trade secret litigation involving ophthalmology clinical trials.
- Due diligence and transaction drafting for major pharmaceutical company's acquisition of molecules for the treatment of degenerative eye diseases.
- Due diligence and transaction drafting for major consumer care company in its acquisition of top-selling line of female health products.
- Due diligence and transaction drafting for drug company's partnership with cancer biotech company.
- Due diligence and transaction drafting for drug company's partnership with medical device company.
- Due diligence and transaction drafting for major pharmaceutical company's acquisition of company focused on kidney fibrosis treatments.
- Due diligence and transaction drafting for major pharmaceutical company's acquisition of company with late-stage compounds for rare hepatic conditions.
- Due diligence for acquisition of complex patent portfolio covering genetically engineered enzymes in the biofuels area.
- Strategic planning and litigation for pharmaceutical companies in ANDA litigation.
- Manage and prosecute patent portfolios for small and large therapeutic molecules, medical devices and genetically modified plants.
- Prepare non-infringement and invalidity opinions in the biotech and genetically modified plant technologies.

Speaking Engagements

- Speaker, "Medical Devices: Regulatory and Intellectual Property Landscape in the U.S.," BIOAlberta, October 2017
- Speaker, "Raising Capital in the United States," BLG Global Access to Capital Seminar Series, December 2016.
- Speaker, "Developing a Road Map for an Efficient Due Diligence Investigation: Preparing for Buy-side and Sell-side Transactions Worldwide and in the U.S.," IP Life Sciences Exchange, November 2016.
- Speaker, The Rockefeller University Biotechnology Forum: *Myriad*, July 2013.
- Speaker, "Patents, Products, and Portfolios: An Expert's In-Depth Review of Key Intellectual Property Issues in Biotech/Pharma," Teleconference hosted by Wells Fargo Securities Healthcare Research Team, December 2011.

- Speaker, "Anatomy of a Patent," Memorial Sloan-Kettering Cancer Center, Guest Speaker, May 2011.
- Instructor, Practising Law Institute, Fundamentals of Patent Prosecution: A Boot Camp for Claim Drafting & Amendment Writing, 2008 and 2009.
- Speaker, Harvard University's Beyond-the-Bench panel, October 2008.
- Speaker, Harvard Medical School, Science in the News seminar series, November 2000.

Publications

- [District Court Broadens Scope of Patent Ineligibility Under § 101 for a Treatment Method](#), *IP Watchdog*, January 18, 2016.

Press Coverage

- Interviewed, "[In conversation with Heather Morehouse Ettinger](#)," *BioTuesdays*, July 14, 2015.